Smith & Nephew Reports Strong Q1 2025 Growth Amid Challenges

Smith & Nephew Snats ( (SNN) ) just unveiled an announcement.

Smith & Nephew reported a positive start to 2025 with a trading update for the first quarter ending March 29, 2025. The company achieved a revenue of $1,407 million, reflecting an underlying growth of 3.1% despite foreign exchange challenges and fewer trading days compared to the previous year. Growth was driven by operational improvements and new product launches, particularly in the US market for hip and knee implants, sports medicine, and advanced wound management. The company’s full-year guidance remains unchanged, with expectations of around 5% underlying revenue growth and a significant increase in trading profit margin. Despite challenges from tariffs and headwinds in China, the company remains optimistic about its growth trajectory and innovation pace.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats receives a solid overall score of 77.0, driven by strong financial performance and positive earnings call sentiment. The company’s impressive revenue and profit growth, coupled with innovation-driven strategies, contribute to a favorable outlook. However, high valuation ratios and technical analysis indicators suggest caution. Challenges in the China market and input cost pressures in Orthopedics remain key risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew is a global medical technology company that specializes in the production of advanced medical devices. The company operates primarily in the fields of orthopaedics, sports medicine, and advanced wound management, focusing on innovative solutions to improve patient outcomes.

YTD Price Performance: 10.79%

Average Trading Volume: 854,802

Technical Sentiment Signal: Hold

Current Market Cap: $11.72B

See more insights into SNN stock on TipRanks’ Stock Analysis page.